No Data
No Data
Express News | Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $16 From $14
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
INFN, VYGR and AMSC Are Among After Hour Movers
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Express News | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Fulcrum Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 87.5% Goldman Sachs → $15 Upgrades Neutral → Buy 03/13/2024 75% RBC Capital → $14 Initiates Cov